Under construction – not a live service

Skip to content

Frontlight Research

Researcher profile · from public sources

Angeles Alvarez Secord

Duke Cancer Institute, United StatesDuke Medical Center, United StatesORCID 0000-0003-0946-76623 publications · 0 trials

This is me: claim the profile

Now

Trials, publications and grants since Nov 2024.

Publication
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research, Feb 2026
Publication
A phase 2 study of pembrolizumab and weekly paclitaxel for platinum-resistant epithelial ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Dec 2025
Publication
Quality-adjusted progression-free survival analysis of veliparib and carboplatin/paclitaxel compared with chemotherapy alone in patients with newly diagnosed ovarian cancer (VELIA/GOG3005): ancillary analysis of a placebo-controlled, phase 3 randomized trial.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Nov 2025

Affiliations

Co-authors

Who links you

Enter another researcher's profile link or ID to see who has published with both of you.

Sources: OpenAlex · Updated 10 Dec 2025This is not me Correct something Object to this profile

Is this you? Request a correction or removal: support@frontlightresearch.com

Report an error

Under construction, not live – Angeles Alvarez Secord: research profile – Frontlight Research